Replies to post #133621 on Biotech Values

[DewDiligence]

The 8-K even refers to this by noting that MNTA stands to gain if they can lessen the regulatory burden for approval of the molecules under consideration.

This, of course, is MNTA’s forte. I would like to see more disclosure on how this feature of the partnership will work, which we may get on tomorrow’s CC.